• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-Deoxy-D-Glucose (2DG)
      • Acacia Cyanophylla Flower
      • Acori Graminei Rhizoma
      • Aegle Marmelos Correa
      • Agaricus Blazei
      • Aged Garlic Extract
      • Aframomum Melegueta
      • Aloe Arborescens
      • Albizia
      • Alpinia Officinarum
      • Alternanthera Sessilis
      • American Ginseng
      • Amygdalin
      • Anacyclus Pyrethrum
      • Angelica Archangelica
      • Angelica Sinensis
      • Antrodia
      • Artichoke Leaf
      • Artocarpin
      • Ajuga Turkestanica
      • Ashwagandha
      • Aspalathin
      • Astragalus Complanatus
      • Avena Sativa
      • Bacopa Monnieri
      • Bavachin
      • Bee Pollen
      • Betulinic Acid
      • Boswellic Acid
      • Brevilin A
      • Campesterol
      • Casticin
      • Chrysin
      • Cinnamomum Zeylanicum
      • Citrullus Colocynthis
      • Citrus Reticulata Peel
      • Codonopsis
      • Costunolide
      • Cucurbitacin D
      • Daidzein
      • Decursin
      • Delphinidin
      • Digitalis Purprea (Digoxin)
      • Diosmin
      • Embelin
      • Gallic Acid
      • Glycitein
      • Glycyrrhizin
      • Hyperforin
      • Icariin
      • Isorhamnetin
      • Isoorientin
      • Isovitexin
      • Jaceosidin
      • Kaempferol
      • Kurarinone
      • Lemon balm
      • Licoricidin
      • Lipoic acid
      • Lupeol
      • Magnolol
      • Mulberry Leaf
      • Naringenin
      • Nobiletin
      • Oleacein
      • Oleanolic acid
      • Oridonin
      • Parthenolide
      • Phloroglucinol
      • Piceatannol
      • Pristimerin
      • Proanthocyanidins
      • Procyanidin B3
      • Pseudolaric acid b
      • Pterostilbene
      • Rutin
      • Solidago Virgaurea
      • Tangeretin
      • Taraxasterol
      • Trichostatin A
      • Wedelolactone
      • Wogonin
      • Yerba Mate
    • ABOUT
    • SCIENTIFIC STUDIES
      • ALLERGIES & CYTOKINES
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • AMPK
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI COVID-19 EFFECTS OF FLAVONOIDS AND POLYPHENOLS (1000 SCIENTIFIC STUDIES)
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • APOPTOSIS
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • CARDIAC GLYCOSIDES
      • CENTENARIANS
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • EPIGENETIC MODIFIERS
      • FGF21
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HMGB1
      • HSP90 INHIBITORS
      • HYPERINSULINEMIA
      • IKK
      • IL-6/STAT3
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INSULIN & AGING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LIFESPAN EXTENSION
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTOR: THE RAPID AGING PATHWAY
      • NEUROINFLAMMATION
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NOOTROPICS
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PHYTOECDYSTEROIDS
      • PPARY2
      • PREMATURE SENESCENCE
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SIRT1 & LONGEVITY
      • SUGAR & AGING
      • STAT3
      • TELOMERE SHORTENING & PREMATURE AGING
    • HOME
    • FAQ
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    Chlorogenic Acid (CGA)
    March 21, 2019
    Luteolin
    April 11, 2019

    MTOR

    “The mammalian target of rapamycin(mTOR), also known as the mechanistic target of rapamycin and FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the MTOR gene.[5][6][7] mTOR is a member of the phosphatidylinositol 3-kinase-related kinase family of protein kinases.[8]

    mTOR links with other proteins and serves as a core component of two distinct protein complexes, mTOR complex 1 and mTOR complex 2, which regulate different cellular processes.[9] In particular, as a core component of both complexes, mTOR functions as a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and transcription.[9][10] As a core component of mTORC2, mTOR also functions as a tyrosine protein kinase that promotes the activation of insulin receptors and insulin-like growth factor 1 receptors.[11]mTORC2 has also been implicated in the control and maintenance of the actin cytoskeleton.[9][12]

    mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids.[10] mTOR also senses cellular nutrient, oxygen, and energy levels.[27] The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue,[28] and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers.[29][30]

    Decreased TOR activity has been found to increase life span in S. cerevisiae, C. elegans, and D. melanogaster.[61][62][63][64] The mTOR inhibitor rapamycin has been confirmed to increase lifespan in mice.[65][66][67][68][69]

    It is hypothesized that some dietary regimes, like caloric restriction and methionine restriction, cause lifespan extension by decreasing mTOR activity.[61][62] Some studies have suggested that mTOR signaling may increase during aging, at least in specific tissues like adipose tissue, and rapamycin may act in part by blocking this increase.[70] An alternative theory is mTOR signaling is an example of antagonistic pleiotropy, and while high mTOR signaling is good during early life, it is maintained at an inappropriately high level in old age. Calorie restriction and methionine restriction may act in part by limiting levels of essential amino acids including leucine and methionine, which are potent activators of mTOR.[71] The administration of leucine into the rat brain has been shown to decrease food intake and body weight via activation of the mTOR pathway in the hypothalamus.[72]

    According to the free radical theory of aging,[73] reactive oxygen species cause damage of mitochondrial proteins and decrease ATP production. Subsequently, via ATP sensitive AMPK, the mTOR pathway is inhibited and ATP consuming protein synthesis is downregulated, since mTORC1 initiates a phosphorylation cascade activating the ribosome.[16] Hence, the proportion of damaged proteins is enhanced. Moreover, disruption of mTORC1 directly inhibits mitochondrial respiration.[74]These positive feedbacks on the aging process are counteracted by protective mechanisms: Decreased mTOR activity (among other factors) upregulates glycolysis[74] and removal of dysfunctional cellular components via autophagy.[73]“ — Wikipedia 

    Simplified in plain English:

    KEEP MTOR TURNED OFF as often as possible.

    MTOR = RAPID AGING.

    You want ZERO amino acids (ie. protein),  glucose or MCT fats during fasting window as these all require insulin and ACTIVATE MTOR. You want ZERO CALORIES. ZERO INSULIN SECRETION.

    Whats left?

    Interstellar Blends, matcha green tea, and black coffee are ok and all inhibit mTOR; utilize these during your fasting window to remain energized, mentally clear, emotionally elevated and feeling all around amazing while staying young by keeping mTOR turned OFF.

    1000 SCIENTIFIC STUDIES

    1. mTOR in Aging , metabolism, and cancer
    2. mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
    3. Rapalogs and mTOR inhibit ors as anti-Aging therapeutics
    4. mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging
    5. Roles of the Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and Aging
    6. calorie restriction : Decelerating mTOR -driven Aging from cells to organisms (including humans)
    7. BMAL1-dependent regulation of the mTOR signaling pathway delays Aging
    8. Increased Mammalian Lifespan and a Segmental and Tissue-Specific Slowing of Aging after Genetic Reduction of mTOR Expression
    9. PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in Aging , cognitive decline and Alzheimer’s disease
    10. Molecular damage in cancer : an argument for mTOR -driven Aging
    11. mTOR signaling in Aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy
    12. Caveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment: Chemoprevention with Rapamycin, an mTOR inhibit or and Anti-Aging Drug
    13. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer , obesity, and Aging
    14. Potential anti-Aging agents suppress the level of constitutive mTOR – and DNA damage- signaling
    15. mTOR signalling: the molecular interface connecting metabolic stress, Aging and cardiovascular diseases
    16. mTOR Signaling from Cellular Senescence to Organismal Aging
    17. Modulating mTOR in Aging and Health
    18. Ral and Rheb GTPase Activating Proteins Integrate mTOR and GTPase Signaling in Aging , Autophagy, and Tumor Cell Invasion
    19. mTOR and autophagy in normal brain Aging and caloric restriction ameliorating age-related cognition deficits
    20. From growing to secreting: New roles for mTOR in Aging cells
    21. mTOR inhibit ion: From Aging to Autism and Beyond
    22. Mechanistic or mammalian target of rapamycin (mTOR ) may determine robustness in young male mice at the cost of accelerated Aging
    23. Effects of Aging and gender on muscle mass and regulation of Akt-mTOR -p70s6k related signaling in the F344BN rat model
    24. M(o)TOR of Aging : mTOR as a universal molecular hypothalamus
    25. mTOR -driven quasi-programmed Aging as a disposable soma theory: Blind watchmaker vs. intelligent designer
    26. longevity Pathways (mTOR , SIRT, insulin /IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
    27. Aging and cancer : can mTOR inhibit ors kill two birds with one drug?
    28. mTOR and its link to the picture of Dorian Gray – re-activation of mTOR promotes Aging
    29. Aberrant mTOR activation in senescence and Aging : A mitochondrial stress response?
    30. The proliferation of amplifying neural progenitor cells is impaired in the Aging brain and restored by the mTOR pathway activation
    31. Kinase mTOR : Regulation and role in maintenance of cellular homeostasis, tumor development, and Aging
    32. HMGA2 regulates the in vitro Aging and proliferation of human umbilical cord blood-derived stromal cells through the mTOR /p70S6K signaling pathway
    33. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow Aging . Coincidences with calorie restriction and mTOR inhibit ion
    34. Coenzyme Q10 inhibit s the Aging of Mesenchymal Stem Cells Induced by D-Galactose through Akt/mTOR Signaling
    35. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven Aging
    36. Ampelopsin attenuates brain Aging of D-gal-induced rats through miR-34a-mediated SIRT1/mTOR signal pathway
    37. Vascular mTOR -dependent mechanisms linking the control of Aging to Alzheimer’s disease
    38. mTOR as Regulator of Lifespan, Aging , and Cellular Senescence: A Mini-Review
    39. restriction on an Energy-Dense Diet Improves Markers of Metabolic Health and Cellular Aging in Mice Through Decreasing Hepatic mTOR Activity
    40. mTOR : at the crossroads of Aging , chaperones, and Alzheimer’s disease
    41. Adaptation to chronic mTOR inhibit ion in cancer and in Aging
    42. The Phosphatidylinositol 3-Kinase/mTOR Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration
    43. Alleviation of senescence and epithelial-mesenchymal transition in Aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK /mTOR signaling
    44. Erythropoietin and mTOR : A “One-Two Punch” for Aging -Related Disorders Accompanied by Enhanced Life Expectancy
    45. mTOR Signaling Fades POMC Neurons during Aging
    46. mTOR signaling plays a critical role in the defects observed in muscle‐derived stem/progenitor cells isolated from a murine model of accelerated Aging
    47. The role of mTOR signaling in Alzheimer disease
    48. Conservative Growth Hormone/IGF-1 and mTOR Signaling Pathways as a Target for Aging and cancer Prevention: Do We Really Have an AntiAging Drug
    49. Gene expression analysis of mTOR pathway: association with human longevity
    50. Rapamycin-Induced insulin Resistance Is Mediated by mTOR C2 Loss and Uncoupled from longevity
    51. Diminished mTOR signaling: a common mode of action for endocrine longevity factors
    52. The Role of mTOR Signaling in Controlling Mammalian Life Span: What a Fungicide Teaches Us About longevity
    53. longevity Pathways (mTOR , SIRT, insulin /IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
    54. PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in Aging , cognitive decline and Alzheimer’s disease
    55. The role of mitochondria in mTOR ‐regulated longevity
    56. Augmented autophagy pathways and mTOR modulation in fibroblasts from long-lived mutant mice
    57. hNAG-1 increases lifespan by regulating energy metabolism and insulin /IGF-1/mTOR signaling
    58. Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression
    59. SIRT1 activator (SRT1720) improves the follicle reserve and prolongs the ovarian lifespan of diet-induced obesity in female mice via activating SIRT1 and suppressing mTOR signaling
    60. Chronic inhibit ion of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
    61. Differential control of ageing and lifespan by isoforms and splice variants across the mTOR network
    62. mTOR , cancer and Transplantation
    63. Defining the Role of mTOR in cancer
    64. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
    65. mTOR and cancer : insights into a complex relationship
    66. mTOR , translation initiation and cancer
    67. mTOR and cancer therapy
    68. The Akt-mTOR tango and its relevance to cancer
    69. mTOR -targeted therapy of cancer with rapamycin derivatives
    70. An expanding role for mTOR in cancer
    71. The mTOR Signalling Pathway in Human cancer
    72. Targeting mTOR signaling for cancer therapy
    73. Targeting the mTOR Signaling Network for cancer Therapy
    74. The translational landscape of mTOR signalling steers cancer initiation and metastasis
    75. Hypoxia signalling through mTOR and the unfolded protein response in cancer
    76. Targeting Pi3k /Akt/mTOR signaling in cancer
    77. Hypoxia-inducible factor determines sensitivity to inhibit ors of mTOR in kidney cancer
    78. mTOR and cancer : many loops in one pathway
    79. mTOR , a novel target in breast cancer : the effect of CCI-779, an mTOR inhibit or, in preclinical models of breast cancer .
    80. mTOR in Aging , metabolism, and cancer
    81. mTOR inhibit ors in cancer therapy
    82. Targeting the mTOR signaling network in cancer
    83. PI3K/Akt/mTOR pathway as a target for cancer therapy. therapy
    84. mTOR signaling and drug development in cancer
    85. Akt-dependent and -independent mechanisms of mTOR regulation in cancer
    86. mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer
    87. Targeting mTOR : prospects for mTOR complex 2 inhibit ors in cancer therapy
    88. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    89. Molecular targets for cancer therapy in the Pi3k /AKT/mTOR pathway
    90. Targeting the mammalian target of rapamycin (mTOR ): a new approach to treating cancer
    91. mTOR signaling: implications for cancer and anticancer therapy
    92. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer
    93. Will mTOR inhibitors make it as cancer drugs?
    94. Activation of the PTEN/mTOR /STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
    95. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    96. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR inhibit or, in Patients With cancer
    97. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    98. Targeting AKT/mTOR and ERK MAPK signaling inhibit s hormone-refractory prostate cancer in a preclinical mouse model
    99. mTOR Complex 2 Is Required for the Development of Prostate cancer Induced by Pten Loss in Mice
    100. Targeting tumorigenesis: development and use of mTOR inhibit ors in cancer therapy
    101. Targeting the Pi3k /AKT/mTOR pathway in estrogen receptor-positive breast cancer
    102. Oral mTOR inhibit or Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic cancer
    103. mTOR mediated anti-cancer drug discovery
    104. Targeting PI3 Kinase/AKT/mTOR Signaling in cancer
    105. Phase II Study of Temsirolimus (CCI-779), a Novel inhibit or of mTOR , in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast cancer
    106. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
    107. inhibit ion of Pi3k /mTOR Leads to Adaptive Resistance in Matrix-Attached cancer Cells
    108. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    109. PI 3-kinase, mTOR , protein synthesis and cancer
    110. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    111. Current treatment strategies for inhibit ing mTOR in cancer
    112. Targeted Therapy for Advanced Prostate cancer : inhibit ion of the Pi3k /Akt/mTOR Pathway
    113. Not all substrates are treated equally: Implications for mTOR , rapamycin-resistance, and cancer therapy
    114. mTOR inhibit ors in the treatment of cancer
    115. Role of Pi3k /AKT/mTOR signaling in the cell cycle progression of human prostate cancer
    116. The Molecular Target of Rapamycin (mTOR ) as a Therapeutic Target Against cancer
    117. Targeting the Pi3k /Akt/mTOR pathway in castration-resistant prostate cancer
    118. Expression of mTOR signaling pathway markers in prostate cancer progression
    119. mTOR Pathway and mTOR inhibit ors as Agents for cancer Therapy
    120. The Pi3k /AKT/mTOR pathway in breast cancer : targets, trials and biomarkers
    121. A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian cancer
    122. Targeting mTOR globally in cancer : Thinking beyond rapamycin
    123. Aspirin inhibit s mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal cancer Cells
    124. The mTOR Pathway: A New Target in cancer Therapy
    125. Phosphatidic acid signaling to mTOR : Signals for the survival of human cancer cells
    126. Adiponectin inhibit s colorectal cancer cell growth through the AMPK /mTOR pathway
    127. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    128. G1 cell cycle progression and the expression of G1 cyclins are regulated by Pi3k /AKT/mTOR /p70S6K1 signaling in human ovarian cancer cells
    129. Targeting Pi3k /AKT/mTOR pathway in non small cell lung cancer
    130. Specific apoptosis induction by the dual Pi3k /mTOR inhibit or NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
    131. Pi3k and mTOR Signaling Pathways in cancer : New Data on Targeted Therapies
    132. Targeting the Pi3k /AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    133. A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
    134. Effects of the mTOR inhibit or sirolimus in patients with hepatocellular and cholangiocellular cancer
    135. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.
    136. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    137. Mechanisms of mTOR inhibit or resistance in cancer therapy
    138. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.
    139. Pi3k /Akt/mTOR inhibit ors in breast cancer
    140. mTOR signaling for biological control and cancer
    141. The Pi3k /AKT/mTOR pathway as a therapeutic target in ovarian cancer
    142. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the Pi3k /Akt/mTOR pathway in prostate cancer radioresistance
    143. Novel Expression Patterns of Pi3k /Akt/mTOR Signaling Pathway Components in Colorectal cancer
    144. Targeting mTOR for cancer Treatment
    145. mTOR Signaling Pathway Is a Target for the Treatment of Colorectal cancer
    146. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
    147. mTOR Signaling Pathway and mTOR inhibit ors in cancer Therapy
    148. Alternative phospholipase D/mTOR survival signal in human breast cancer cells
    149. Quercetin induces protective autophagy in gastric cancer cells: Involvement of Akt-mTOR – and hypoxia-induced factor 1α-mediated signaling
    150. inhibit ors of the Pi3k /Akt/mTOR Pathway: New Hope for Breast cancer Patients
    151. A phase 2 study with a daily regimen of the oral mTOR inhibit or RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
    152. mTOR inhibit ors in cancer therapy
    153. GDC-0980 Is a Novel Class I Pi3k /mTOR Kinase inhibit or with Robust Activity in cancer Models Driven by the Pi3k Pathway
    154. mTOR kinase inhibit ors as potential cancer therapeutic drugs
    155. Expanding therapeutic targets in bladder cancer : the Pi3k /Akt/mTOR pathway
    156. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
    157. Genetic Variations in the Pi3k /PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal cancer Patients Treated With Chemoradiotherapy
    158. AKT and cancer —Is it all mTOR ?
    159. Targeting the Pi3k -AKT-mTOR signaling network in cancer
    160. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells
    161. New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
    162. The Potential Role of mTOR inhibit ors in Non-Small Cell Lung cancer
    163. Potential Targets for Prevention of Colorectal cancer : a Focus on Pi3k /Akt/mTOR and Wnt Pathways
    164. Oxygen-independent Regulation of HIF-1: Novel Involvement of Pi3k / AKT/mTOR Pathway in cancer
    165. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.
    166. mTOR pathway in colorectal cancer : an update
    167. mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.
    168. JAK2/STAT5 inhibit ion Circumvents Resistance to Pi3k /mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast cancer
    169. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibit ory drugs
    170. Targeting mTOR signaling in lung cancer
    171. Pi3k /Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application
    172. mTOR signaling in human cancer
    173. Compound C induces protective autophagy in cancer cells through AMPK inhibit ion-independent blockade of Akt/mTOR pathway
    174. Pi3k -AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
    175. mTOR and cancer : reason for dancing at the crossroads?
    176. Enhancing mTOR -targeted cancer therapy
    177. Targeting mTOR pathway: A new concept in cancer therapy
    178. Hypoxia inhibit s Protein Synthesis through a 4E-BP1 and Elongation Factor 2 Kinase Pathway Controlled by mTOR and Uncoupled in Breast cancer Cells
    179. Autophagy upregulation by inhibit ors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
    180. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibit ors
    181. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.
    182. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer
    183. Deciphering the Role of Pi3k /Akt/mTOR Pathway in Breast cancer Biology and Pathogenesis
    184. Targeting mTOR dependency in pancreatic cancer
    185. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells
    186. mTOR as a Target for cancer Therapy
    187. PLC and Pi3k /Akt/mTOR signalling in disease and cancer
    188. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway
    189. Down‐regulation of Notch‐1 and Jagged‐1 inhibit s prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR , and NF‐κB signaling pathways
    190. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells
    191. In vivo antitumor effect of the mTOR inhibit or CCI‐779 and gemcitabine in xenograft models of human pancreatic cancer
    192. Antidiabetic Drug Metformin Prevents Progression of Pancreatic cancer by Targeting in Part cancer Stem Cells and mTOR Signaling
    193. The oral mTOR inhibit or RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer : Results of a phase I study with pharmacokinetics
    194. mTOR inhibit ors for hepatocellular cancer : a forward-moving target
    195. Rapamycin and mTOR : a serendipitous discovery and implications for breast cancer
    196. Mammalian Target of Rapamycin (mTOR ) inhibit ors as Anti-cancer Agents
    197. Metformin promotes progesterone receptor expression via inhibit ion of mammalian target of rapamycin (mTOR ) in endometrial cancer cells
    198. Relation between outcomes and localisation of p-mTOR expression in gastric cancer
    199. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    200. Development of Pi3k /AKT/mTOR Pathway inhibit ors and Their Application in Personalized Therapy for Non–Small-Cell Lung cancer
    201. A phase II trial of the mTOR inhibit or AP23573 as a single agent in advanced endometrial cancer
    202. Rottlerin induces autophagy which leads to apoptotic cell death through inhibit ion of Pi3k /Akt/mTOR pathway in human pancreatic cancer stem cells
    203. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR /S6K2 signaling pathway
    204. Pi3k /Akt/mTOR Pathway inhibit ors in cancer : A Perspective on Clinical Progress
    205. The Pharmacology of mTOR inhibit ion
    206. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
    207. The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast cancer
    208. Simvastatin inhibit s Renal cancer Cell Growth and Metastasis via AKT/mTOR , ERK and JAK2/STAT3 Pathway
    209. The Pi3k /AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance
    210. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via Pi3k /Akt/mTOR signaling pathway
    211. Recent Clinical Trials of mTOR -Targeted cancer Therapies
    212. Docosahexaenoic acid induces autophagy through p53/AMPK /mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53
    213. Dietary flavonoid fisetin: A novel dual inhibit or of Pi3k /Akt and mTOR for prostate cancer management
    214. Thioridazine induces apoptosis by targeting the Pi3k /Akt/mTOR pathway in cervical and endometrial cancer cells
    215. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
    216. Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2‐overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation
    217. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
    218. The VEGF pathway and the AKT/mTOR /p70S6K1 signalling pathway in human epithelial ovarian cancer
    219. Phase I trial of oral mTOR inhibit or everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
    220. Effects of a combined treatment with mTOR inhibit or RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
    221. The Importance of the Pi3k /AKT/mTOR Pathway in the Progression of Ovarian cancer
    222. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells
    223. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer
    224. Molecular damage in cancer : an argument for mTOR -driven Aging
    225. mTOR in renal cell cancer : modulator of tumor biology and therapeutic target
    226. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer , obesity, and Aging
    227. Allosteric and ATP-competitive kinase inhibit ors of mTOR for cancer treatment
    228. A review of oral toxicity associated with mTOR inhibit or therapy in cancer patients
    229. LKB1/AMPK /mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology
    230. Current clinical regulation of Pi3k /PTEN/Akt/mTOR signalling in treatment of human cancer
    231. Deciphering downstream gene targets of Pi3k /mTOR /p70S6K pathway in breast cancer
    232. Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in cancer Cells
    233. Pi3k /AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    234. Temsirolimus, an mTOR inhibit or, enhances anti-tumour effects of heat shock protein cancer vaccines
    235. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibit ion of cell proliferation and modulation of the mTOR pathway
    236. Silibinin inhibit s hypoxia-inducible factor-1α and mTOR /p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy
    237. mTOR Signaling in cancer Cell Motility and Tumor Metastasis
    238. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables
    239. Pi3k /Akt/mTOR pathway inhibit ors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
    240. The expanding role of mTOR in cancer cell growth and proliferation
    241. mTOR as a therapeutic target in patients with gastric cancer
    242. mTOR -independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibit ors
    243. mTOR inhibit or Treatment of Pancreatic cancer in a Patient With Peutz-Jeghers Syndrome
    244. Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (Pi3k )/Mammalian Target of Rapamycin (mTOR ) Kinase inhibit or (GDC-0980) for the Treatment of cancer
    245. The Dual Pi3k /mTOR inhibit or NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal cancer
    246. TGF-β Effects on Prostate cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of Pi3k /AKT/mTOR Pathway
    247. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.
    248. Fucoidan from Seaweed Fucus vesiculosus inhibit s Migration and Invasion of Human Lung cancer Cell via Pi3k -Akt-mTOR Pathways
    249. Integrated preclinical and clinical development of mTOR inhibit ors in pancreatic cancer
    250. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
    251. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the Pi3k /Akt/mTOR signaling pathway
    252. Genetic variations in Pi3k -AKT-mTOR pathway and bladder cancer risk
    253. Targeting Pi3k /Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
    254. Simultaneous inhibit ion of mTOR C1 and mTOR C2 by mTOR kinase inhibit or AZD8055 induces autophagy and cell death in cancer cells
    255. Targeting mTOR network in colorectal cancer therapy
    256. Targeting the Pi3k /Akt/mTOR Axis by Apigenin for cancer Prevention
    257. Pi3k /Akt/mTOR signaling in medullary thyroid cancer : a promising molecular target for cancer therapy
    258. Genomic Loss of Tumor Suppressor miRNA-204 Promotes cancer Cell Migration and Invasion by Activating AKT/mTOR /Rac1 Signaling and Actin Reorganization
    259. Therapeutic targeting of the mTOR ‐signalling pathway in cancer : benefits and limitations
    260. From Rapa Nui to rapamycin: targeting Pi3k /Akt/mTOR for cancer therapy
    261. Pi3k /AKT/mTOR inhibit ors In Ovarian cancer
    262. Metformin and the mTOR inhibit or Everolimus (RAD001) Sensitize Breast cancer Cells to the Cytotoxic Effect of Chemotherapeutic Drugs In Vitro
    263. Resveratrol enhances the anti-tumor activity of the mTOR inhibit or rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling
    264. A liaison between mTOR signaling, ribosome biogenesis and cancer
    265. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
    266. Dual inhibit ion of EGFR and mTOR pathways in small cell lung cancer
    267. Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets
    268. Repurposing of Metformin and Aspirin by Targeting AMPK-mTOR and Inflammation for Pancreatic Cancer Prevention and Treatment
    269. Licorice and Licochalcone-A Induce Autophagy in LNCaP Prostate cancer Cells by Suppression of Bcl-2 Expression and the mTOR Pathway
    270. LKB1/AMPK /mTOR Signaling Pathway in Non-small-cell Lung cancer
    271. Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR inhibit ors and Metformin in Pancreatic cancer Cells
    272. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
    273. Prognostic role of p‐mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer
    274. E2F1 inhibit s c-Myc-Driven Apoptosis via PIK3CA/Akt/mTOR and COX-2 in a Mouse Model of Human Liver cancer
    275. mTOR Signaling in Protein Translation Regulation: Implications in cancer Genesis and Therapeutic Interventions
    276. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer
    277. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR , PTEN , STK11 , RPKAA1 , PRKAG2 , TSC1 , TSC2 , Pi3k and Akt1
    278. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
    279. Curcumin inhibit s the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
    280. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    281. Targeting the Pi3k /Akt/mTOR Pathway for Breast cancer Therapy
    282. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway
    283. Overcoming acquired resistance to letrozole by targeting the Pi3k /AKT/mTOR pathway in breast cancer cell clones
    284. Dissecting the role of mTOR : Lessons from mTOR inhibit ors
    285. 6-Shogaol, an Active Constituent of Dietary Ginger, Induces Autophagy by inhibit ing the AKT/mTOR Pathway in Human Non-Small Cell Lung cancer A549 Cells
    286. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.
    287. Glucose metabolism and cancer
    288. Rhodiola rosea extract s and salidroside decrease the growth of bladder cancer cell lines via inhibit ion of the mTOR pathway and induction of autophagy
    289. Targeted Regulation of Pi3k /Akt/mTOR /NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for cancer Therapy
    290. Current Status and Challenges Associated with Targeting mTOR for cancer Therapy
    291. Pi3k -AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate cancer Cells
    292. The mTOR Pathway in Breast cancer
    293. mTOR inhibit ion reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels
    294. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.
    295. HIF1α Regulates mTOR Signaling and Viability of Prostate cancer Stem Cells
    296. Involvement of Akt-1 and mTOR in Sensitivity of Breast cancer to Targeted Therapy
    297. inhibit ion of mTOR Signaling by Quercetin in cancer Treatment and Prevention
    298. Plumbagin induces apoptotic and autophagic cell death through inhibit ion of the Pi3k /Akt/mTOR pathway in human non-small cell lung cancer cells
    299. Overexpression of the μ-Opioid Receptor in Human Non-Small Cell Lung cancer Promotes Akt and mTOR Activation, Tumor Growth, and Metastasis
    300. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
    301. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.
    302. Attenuated mTOR Signaling and Enhanced Autophagy in Adipocytes from Obese Patients with Type 2 diabetes
    303. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    304. The Tuberin/mTOR Pathway Promotes Apoptosis of Tubular Epithelial Cells in diabetes
    305. mTOR inhibit ors and diabetes
    306. The role of mTOR in the adaptation and failure of β‐cells in type 2 diabetes
    307. mTOR : Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus
    308. The role of mammalian target of rapamycin (mTOR ) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes
    309. Insights for oxidative stress and mTOR Signaling in Myocardial Ischemia/Reperfusion Injury under diabetes
    310. Phospho-mTOR : A novel target in regulation of renal lipid metabolism abnormality of diabetes
    311. mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer’s disease
    312. Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes
    313. Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR
    314. Leucine Stimulates insulin Secretion via Down-regulation of Surface Expression of Adrenergic α2A Receptor through the mTOR (Mammalian Target of Rapamycin) Pathway
      IMPLICATION IN NEW-ONSET diabetes IN RENAL TRANSPLANTATION
    315. The role of mTOR in lipid homeostasis and diabetes progression
    316. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes
    317. The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 diabetes Mellitus
    318. Investigation of Pi3k /PKB/mTOR /S6K1 signaling pathway in relationship of type 2 diabetes and Alzheimer’s disease
    319. Association of Pi3k /AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese
    320. diabetes Diminishes Phosphatidic Acid in the Retina: A Putative Mediator for Reduced mTOR Signaling and Increased Neuronal Cell Death
    321. mTOR and Cardiovascular Diseases: Diabetes Mellitus.
    322. Analysis of single nucleotide polymorphisms implicate mTOR signalling in the development of new-onset diabetes after transplantation
    323. microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus
    324. 1,25(OH)2D3 improves cardiac dysfunction, hypertrophy, and fibrosis through PARP1/SIRT1/mTOR ‐related mechanisms in type 1 diabetes
    325. High glucose induces formation of tau hyperphosphorylation via Cav-1-mTOR pathway: A potential molecular mechanism for diabetes -induced cognitive dysfunction
    326. Supplementation with polyunsaturated fatty acids in pregnant rats with mild diabetes normalizes placental PPARγ and mTOR signaling in female offspring developing gestational diabetes
    327. Associations between INSR and mTOR polymorphisms in type 2 diabetes mellitus and diabetic nephropathy in a Northeast Chinese Han population
    328. Anabolic resistance does not explain sarcopenia in patients with type 2 diabetes mellitus, compared with healthy controls, despite reduced mTOR pathway activity
    329. Tuberin and mTOR , a key apoptotic pathway indiabetes
    330. inhibit ion of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan
    331. Amino Acid and insulin Signaling via the mTOR /p70 S6 Kinase Pathway
      A NEGATIVE FEEDBACK MECHANISM LEADING TO insulin RESISTANCE IN SKELETAL MUSCLE CELLS
    332. Down-regulation of placental mTOR , insulin /IGF-I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon
    333. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibit ion of insulin signaling through insulin receptor substrate-1
    334. Nutrients Suppress Phosphatidylinositol 3-Kinase/Akt Signaling via Raptor-Dependent mTOR -Mediated insulin Receptor Substrate 1 Phosphorylation
    335. insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase
    336. Stimulation of the insulin /mTOR pathway delays cone death in a mouse model of retinitis pigmentosa
    337. mTOR ‐dependent stimulation of the association of eIF4G and eIF3 by insulin
    338. MAP kinases and mTOR mediate insulin -induced phosphorylation of insulin Receptor Substrate-1 on serine residues 307, 612 and 632
    339. Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways.
    340. Amino Acids and insulin Control Autophagic Proteolysis through Different Signaling Pathways in Relation to mTOR in Isolated Rat Hepatocytes
    341. Distinct Signaling Events Downstream of mTOR Cooperate To Mediate the Effects of Amino Acids and insulin on Initiation Factor 4E-Binding Proteins
    342. Regulation of insulin signalling by hyperinsulin aemia: role of IRS-1/2 serine phosphorylation and the mTOR /p70 S6K pathway
    343. Mammalian target of rapamycin (mTOR ) inhibit ion activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin -like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibit ion of both pathways
    344. Long‐chain omega‐3 fatty acids regulate bovine whole‐body protein metabolism by promoting muscle insulin signalling to the Akt–mTOR –S6K1 pathway and insulin sensitivity
    345. Activation of Mammalian Target of Rapamycin (mTOR ) by insulin Is Associated with Stimulation of 4EBP1 Binding to Dimeric mTOR Complex 1
    346. insulin – and Leptin-Mediated Control of Aquaglyceroporins in Human Adipocytes and Hepatocytes Is Mediated via the Pi3k /Akt/mTOR Signaling Cascade
    347. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors.
    348. Chronic mTOR inhibit ion by rapamycin induces muscle insulin resistance despite weight loss in rats
    349. Insulin Stimulates Mitochondrial Fusion and Function in Cardiomyocytes via the Akt-mTOR-NFkB-Opa-1 Signaling Pathway
    350. Glycerolipid signals alter mTOR complex 2 (mTOR C2) to diminish insulin signaling
    351. insulin promotes dendritic spine and synapse formation by the Pi3k /Akt/mTOR and Rac1 signaling pathways
    352. The TSC-mTOR Pathway Mediates Translational Activation of TOP mRNAs by insulin Largely in a Raptor- or Rictor-Independent Manner
    353. insulin Receptor Substrate-2 Proteasomal Degradation Mediated by a Mammalian Target of Rapamycin (mTOR )-induced Negative Feedback Down-regulates Protein Kinase B-mediated Signaling Pathway in β-Cells
    354. IKKβ suppression of TSC1 function links the mTOR pathway with insulin resistance
    355. The Cardioprotection of the insulin -Mediated Pi3k /Akt/mTOR Signaling Pathway
    356. Mammalian target of rapamycin (mTOR ) is involved in the neuronal differentiation of neural progenitors induced by insulin
    357. Maternal Protein restriction in the Rat inhibit s Placental insulin , mTOR , and STAT3 Signaling and Down-Regulates Placental Amino Acid Transporters
    358. Hepatitis C Virus Activates the mTOR /S6K1 Signaling Pathway in inhibit ing IRS-1 Function for insulin Resistance
    359. The insulin -like Growth Factor-I–mTOR Signaling Pathway Induces the Mitochondrial Pyrimidine Nucleotide Carrier to Promote Cell Growth
    360. insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibit or temsirolimus in patients with metastatic adrenocortical carcinoma
    361. Glucose phosphorylation is required for insulin -dependent mTOR signalling in the heart
    362. Activation of mTOR /p70S6 kinase by ANG II inhibit s insulin -stimulated endothelial nitric oxide synthase and vasodilation
    363. mTOR inhibit ion with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
    364. Amino acids are necessary for the insulin -induced activation of mTOR /S6K1 signaling and protein synthesis in healthy and insulin resistant human skeletal muscle
    365. Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice
    366. insulin -Like Growth Factor I-Mediated Skeletal Muscle Hypertrophy Is Characterized by Increased mTOR -p70S6K Signaling without Increased Akt Phosphorylation
    367. The Pi3k /Akt/mTOR signaling pathway mediates insulin -like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells
    368. insulin ‐like growth factor‐1 (IGF‐1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR ) pathway
    369. mTOR Complex 2 Regulates Proper Turnover of insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8
    370. Both Wnt and mTOR signaling pathways are involved in insulin -stimulated proto-oncogene expression in intestinal cells
    371. Zinc stimulates the activity of the insulin – and nutrient-regulated protein kinase mTOR
    372. Resistin Promotes Cardiac Hypertrophy via the AMP-activated Protein Kinase/Mammalian Target of Rapamycin (AMPK /mTOR ) and c-Jun N-terminal Kinase/insulin Receptor Substrate 1 (JNK/IRS1) Pathways
    373. Role of the PI3-kinase/mTOR pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver
    374. Exercise training reduces insulin resistance and upregulates the mTOR /p70S6k pathway in cardiac muscle of diet‐induced obesity rats
    375. Leucine Activates Pancreatic Translational Machinery in Rats and Mice through mTOR Independently of CCK and insulin
    376. Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-insulin –like Growth Factor I Receptor Monoclonal Antibody
    377. insulin Potentiates Ca2+ Signaling and Phosphatidylinositol 4,5-Bisphosphate Hydrolysis Induced by Gq Protein-Coupled Receptor Agonists through an mTOR -Dependent Pathway
    378. insulin -induced stimulation of JNK and the PI 3-kinase/mTOR pathway leads to phosphorylation of serine 318 of IRS-1 in C2C12 myotubes
    379. Tissue-Specific Responses of IGF-1/insulin and mTOR Signaling in calorie Restricted Rats
    380. mTOR C2 promotes type I insulin -like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR
    381. insulin -like growth factor-I inhibit s dexamethasone-induced proteolysis in cultured L6 myotubes through Pi3k /Akt/GSK-3β and Pi3k /Akt/mTOR -dependent mechanisms
    382. The role of AMPK /mTOR /S6K1 signaling axis in mediating the physiological process of exercise-induced insulin sensitization in skeletal muscle of C57BL/6 mice
    383. Glucose Induces Mouse β-Cell Proliferation via IRS2, MTOR, and Cyclin D2 but Not the Insulin Receptor.
    384. insulin Promotes Glucose Consumption via Regulation of miR-99a/mTOR /PKM2 Pathway
    385. insulin -induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR : studies on the function of Ser675 and Ser907
    386. Protein Ingestion Induces Muscle Insulin Resistance Independent of Leucine-Mediated mTOR Activation.
    387. Salmonella enterica Typhimurium infection causes metabolic changes in chicken muscle involving AMPK , fatty acid and insulin /mTOR signaling
    388. inhibit ion of the mTOR /p70S6K pathway is not involved in the insulin -sensitizing effect of AMPK on cardiac glucose uptake
    389. Acute mTOR inhibit ion induces insulin resistance and alters substrate utilization in vivo
    390. Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells
    391. Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats
    392. Implication of RICTOR in the mTOR inhibit or-mediated induction of insulin -like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
    393. Cardiac overexpression of insulin -like growth factor 1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction but not hypertrophy: Roles of Akt, mTOR , GSK3β, and PTEN
    394. Palmitate Induced insulin Resistance by PKCtheta-Dependent Activation of mTOR /S6K Pathway in C2C12 Myotubes
    395. insulin fails to enhance mTOR phosphorylation, mitochondrial protein synthesis, and ATP production in human skeletal muscle without amino acid replacement
    396. Mechanistic target of rapamycin (mTOR ): a point of convergence in the action of insulin /IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells
    397. Raptor Binds the SAIN (Shc and IRS-1 NPXY Binding) Domain of insulin Receptor Substrate-1 (IRS-1) and Regulates the Phosphorylation of IRS-1 at Ser-636/639 by mTOR
    398. Quantification of the effect of amino acids on an integrated mTOR and insulin signaling pathway
    399. The Mechanism of insulin -stimulated 4E-BP Protein Binding to Mammalian Target of Rapamycin (mTOR ) Complex 1 and Its Contribution to mTOR Complex 1 Signaling
    400. Activation of placental insulin and mTOR signaling in a mouse model of maternal obesity associated with fetal overgrowth
    401. Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling
    402. Adipocyte-specific deletion of mTOR inhibit s adipose tissue development and causes insulin resistance in mice
    403. insulin inhibit ion of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation
    404. PKCζ Is Essential for Pancreatic β-Cell Replication During Insulin Resistance by Regulating mTOR and Cyclin-D2.
    405. Cardamonin Ameliorates insulin Resistance Induced by High insulin and High Glucose through the mTOR and Signal Pathway
    406. inhibit ion of PI-3 kinase/Akt/mTOR , but not calcineurin signaling, reverses insulin -like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function
    407. Evodiamine inhibit s insulin -Stimulated mTOR -S6K Activation and IRS1 Serine Phosphorylation in Adipocytes and Improves Glucose Tolerance in Obese/Diabetic Mice
    408. insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1
    409. mTOR -Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1
    410. The inhibit ion of insulin -stimulated Proliferation of Vascular Smooth Muscle Cells by Rosiglitazone Is Mediated by the Akt-mTOR -P70S6K Pathway
    411. insulin regulation of hepatic insulin -like growth factor-binding protein-1 (IGFBP-1) gene expression and mammalian target of rapamycin (mTOR ) signalling is impaired by the presence of hydrogen peroxide
    412. Anthocyanin-rich mulberry fruit improves insulin resistance and protects hepatocytes against oxidative stress during hyperglycemia by regulating AMPK /ACC/mTOR pathway
    413. mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer’s disease
    414. Impaired overload-induced hypertrophy is associated with diminished mTOR signaling in insulin -resistant skeletal muscle of the obese Zucker rat
    415. Anti-inflammatory action of insulin via induction of Gadd45-β transcription by the mTOR signaling pathway
    416. In Human Endothelial Cells Amino Acids Inhibit Insulin-induced Akt and ERK1/2 Phosphorylation by an mTOR-dependent Mechanism
    417. Activation of the hexosamine pathway leads to phosphorylation of IRS-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mTOR insulin biosynthetic pathway in RIN pancreatic {beta}-cells
    418. Essential Amino Acids Improve insulin Activation of Akt/mTOR Signaling in Soleus Muscle of Aged Rats
    419. Akt/mTOR Role in Human Foetoplacental Vascular insulin Resistance in Diseases of Pregnancy
    420. Glycerol-3-phosphate acyltransferase-4-deficient mice are protected from diet-induced insulin resistance by the enhanced association of mTOR and rictor
    421. The Regulation of Lipid Deposition by insulin in Goose Liver Cells Is Mediated by the Pi3k -AKT-mTOR Signaling Pathway
    422. Pectic Bee Pollen Polysaccharide from Rosa rugosa Alleviates Diet-Induced Hepatic Steatosis and insulin Resistance via Induction of AMPK /mTOR -Mediated Autophagy
    423. Reduction of insulin signalling pathway IRS‐1/IRS‐2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid‐treated rats
    424. Flavanol‐rich lychee fruit extract alleviates diet‐induced insulin resistance via suppressing mTOR /SREBP‐1 mediated lipogenesis in liver and restoring insulin signaling in skeletal muscle
    425. insulin -like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the Pi3k /Akt/mTOR signaling pathway
    426. Melanocortin-4 receptor activation promotes insulin -stimulated mTOR signaling
    427. Heparin-Binding EGF-Like Growth Factor (HB-EGF) Mediates 5-HT-Induced insulin Resistance Through Activation of EGF Receptor-ERK1/2-mTOR Pathway
    428. Zinc stimulates glucose consumption by modulating the insulin signaling pathway in L6 myotubes: essential roles of Akt–GLUT4, GSK3β and mTOR –S6K1
    429. Amino acid-sensing mTOR signaling is involved in modulation of lipolysis by chronic insulin treatment in adipocytes
    430. Overexpression of Kinase-Dead mTOR Impairs Glucose Homeostasis by Regulating Insulin Secretion and Not β-Cell Mass.
    431. Combination of the mammalian target of rapamycin (mTOR ) inhibit or everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibit or NVP-AEW-541: A mechanistic based anti-tumor strategy
    432. Exercise improves skeletal muscle insulin resistance without reduced basal mTOR /S6K1 signaling in rats fed a high-fat diet
    433. insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the Pi3k /mTOR pathway
    434. The dual targeting of insulin and insulin -like growth factor 1 receptor enhances the mTOR inhibit or-mediated antitumor efficacy in hepatocellular carcinoma
    435. insulin activation of vacuolar protein sorting 34 mediates localized phosphatidylinositol 3-phosphate production at lamellipodia and activation of mTOR /S6K1
    436. Attenuation of insulin resistance in rats by agmatine: role of SREBP-1c, mTOR and GLUT-2
    437. mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine307 residues after burn
    438. Development of a model describing regulation of casein synthesis by the mammalian target of rapamycin (mTOR ) signaling pathway in response to insulin , amino acids, and acetate
    439. Judicious Toggling of mTOR Activity to Combat insulin Resistance and cancer : Current Evidence and Perspectives
    440. Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer’s disease
    441. insulin Stimulates Goose Liver Cell Growth by Activating Pi3k -AKT-mTOR Signal Pathway
    442. The effects of amino acids on glucose metabolism of isolated rat skeletal muscle are independent of insulin and the mTOR /S6K pathway
    443. Exercise and dietary change ameliorate high fat diet induced obesity and insulin resistance via mTOR signaling pathway
    444. insulin -like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibit ion of the mTOR pathway in prostate cancer
    445. insulin Increases Sestrin 2 Content by Reducing Its Degradation through the Pi3k /mTOR Signaling Pathway
    446. calorie restriction : Decelerating mTOR -driven Aging from cells to organisms (including humans)
    447. mTOR and autophagy in normal brain Aging and caloric restriction ameliorating age-related cognition deficits
    448. Effects of Intermittent and Chronic calorie restriction on Mammalian Target of Rapamycin (mTOR ) and IGF-I Signaling Pathways in Mammary Fat Pad Tissues and Mammary Tumors
    449. Effect of caloric restriction on the SIRT1/mTOR signaling pathways in senile mice
    450. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow Aging . Coincidences with calorie restriction and mTOR inhibit ion
    451. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR
    452. Systematic gene expression profile of hypothalamus in calorie -restricted mice implicates the involvement of mTOR signaling in neuroprotective activity
    453. mTOR signaling and ubiquitin-proteosome gene expression in the preservation of fat free mass following high protein, calorie restricted weight loss
    454. fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling
    455. Muscle Wasting in fasting Requires Activation of NF-κB and inhibit ion of AKT/Mechanistic Target of Rapamycin (mTOR ) by the Protein Acetylase, GCN5
    456. fasting glucose and triglycerides as biomarkers of mTOR inhibit ion, evidence of a categorical response.
    457. mTOR C1 controls fasting -induced ketogenesis and its modulation by ageing
    458. The ketogenic diet inhibit s the mammalian target of rapamycin (mTOR ) pathway
    459. Rapamycin passes the torch: a new generation of mTOR inhibit ors
    460. Pi3k /AKT/mTOR inhibit ors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
    461. Next-generation mTOR inhibit ors in clinical oncology: how pathway complexity informs therapeutic strategy
    462. mTOR inhibit ors: An overview
    463. Updates of mTOR inhibit ors
    464. PIK3CA Mutations in Patients with Advanced cancer s Treated with Pi3k /AKT/mTOR Axis inhibit ors
    465. Enhanced radiation damage of tumor vasculature by mTOR inhibit ors
    466. AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR ) inhibit ors by Regulating Cyclin D1 and c-myc Expression
    467. Ras/Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR inhibit ors: Rationale and Importance to inhibit ing These Pathways in Human Health
    468. Picking the Point of inhibit ion: A Comparative Review of Pi3k /AKT/mTOR Pathway inhibit ors
    469. Targeting the mTOR kinase domain: the second generation of mTOR inhibit ors
    470. Pilot study of the combination of EGFR and mTOR inhibit ors in recurrent malignant gliomas
    471. mTOR Signaling, Function, Novel inhibit ors, and Therapeutic Targets
    472. Strategies for the management of adverse events associated with mTOR inhibit ors
    473. mTOR inhibit ors-induced proteinuria: mechanisms, significance, and management
    474. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
    475. Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR ) inhibit ors: Effects on mTOR C1 and Akt Signaling Lead to Improved Survival and Function
    476. Combinations of BRAF, MEK, and Pi3k /mTOR inhibit ors Overcome Acquired Resistance to the BRAF inhibit or GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
    477. Assessing PIK3CA and PTEN in Early-Phase Trials with Pi3k /AKT/mTOR inhibit ors
    478. Pi3k and mTOR inhibit ors — a new generation of targeted anticancer agents
    479. mTOR inhibit or/proliferation signal inhibit ors: entering or leaving the field?
    480. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
    481. Predicted mechanisms of resistance to mTOR inhibit ors
    482. mTOR inhibit ors in Tuberous Sclerosis Complex
    483. The role of mTOR inhibitors in the management of posttransplant malignancy.
    484. Pushing the Envelope in the mTOR Pathway: The Second Generation of inhibit ors
    485. IRS-1: Auditing the effectiveness of mTOR inhibit ors
    486. mTOR inhibit ors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
    487. mTOR inhibit ors in Polycystic Kidney Disease
    488. mTOR inhibit ors in Advanced Renal Cell Carcinoma
    489. inhibit ors of mTOR
    490. mTOR inhibit ors in renal cell carcinoma
    491. The pleiotropic effects of mTOR inhibit ors.
    492. The emerging safety profile of mTOR inhibit ors, a novel class of anticancer agents
    493. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
    494. Rapamycin and mTOR kinase inhibit ors
    495. Current development of the second generation of mTOR inhibit ors as anticancer agents
    496. Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR ) inhibit ors
    497. Potent antifibrotic activity of mTOR inhibit ors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis
    498. Replacing calcineurin inhibit ors with mTOR inhibit ors in children
    499. Aspects of mTOR biology and the use of mTOR inhibit ors in non-Hodgkin’s lymphoma
    500. Differentiating mTOR inhibit ors in renal cell carcinoma
    501. Mammalian target of rapamycin (mTOR ) inhibit ors
    502. mTOR inhibit ors Alone and in Combination with JAK2 inhibit ors Effectively inhibit Cells of Myeloproliferative Neoplasms
    503. Targeted inhibit ion of mTOR C1 and mTOR C2 by active-site mTOR inhibit ors has cytotoxic effects in T-cell acute lymphoblastic leukemia
    504. Increased Incidence of Angioedema with ACE inhibit ors in Combination with mTOR inhibit ors in Kidney Transplant Recipients
    505. mTOR inhibit ors and their clinical application in cervical, endometrial and ovarian cancer s: A critical review
    506. Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR ) inhibit ors and Characterization of Their Binding Kinetics
    507. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibit ors in human ovarian carcinoma
    508. Review of combination therapy with mTOR inhibit ors and tacrolimus minimization after transplantation
    509. Therapeutic polymeric nanoparticles with mTOR inhibit ors and methods of making and using same
    510. Pneumonitis associated with mTOR inhibit ors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome
    511. MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR inhibit ors
    512. Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR inhibit ors in Metastatic Renal Cell Carcinoma
    513. Updating progress in sarcoma therapy with mTOR inhibit ors
    514. mTOR inhibit ors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma
    515. Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR inhibit ors in Neuroendocrine Tumor Therapy
    516. Mammalian Target of Rapamycin (mTOR ) inhibit ors
    517. Synergic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibit ors on pancreatic cancer cells
    518. Metabolic complications with the use of mTOR inhibit ors for cancer therapy
    519. A critical review of mTOR inhibit ors and epilepsy: from basic science to clinical trials
    520. mTOR inhibit ors in breast cancer : A systematic review
    521. Biologic rationale and clinical activity of mTOR inhibit ors in gynecological cancer
    522. Defining biomarkers to predict sensitivity to Pi3k /Akt/mTOR pathway inhibit ors in breast cancer
    523. Comparison of the effects of the Pi3k /mTOR inhibit ors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
    524. Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR inhibit ors for the Treatment of cancer
    525. Focus on mTOR inhibit ors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes
    526. Preclinical evaluation of dual Pi3k –mTOR inhibit ors and histone deacetylase inhibit ors in head and neck squamous cell carcinoma
    527. Induction of autophagy with catalytic mTOR inhibit ors reduces huntingtin aggregates in a neuronal cell model
    528. Comparative Analysis of Adverse Events Requiring Suspension of mTOR inhibit ors: Everolimus versus Sirolimus
    529. Mammalian target of rapamycin (mTOR ) inhibit ors slow skin carcinogenesis, but impair wound healing
    530. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibit ors
    531. mTOR pathway and mTOR inhibit ors in head and neck cancer
    532. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress : interactions with mTOR inhibit ors
    533. mTOR inhibit ors at a Glance
    534. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibit ors? A systematic review of randomized controlled trials
    535. Clinical development of mTOR inhibitors in breast cancer
    536. inhibit ors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation
    537. Incomplete inhibit ion of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibit ors
    538. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibit ors for malignancy. A meta-analysis of published trials
    539. Cancer and mTOR Inhibitors in Transplant Recipients.
    540. Antitumor activity of pimasertib, a selective MEK 1/2 inhibit or, in combination with Pi3k /mTOR inhibit ors or with multi‐targeted kinase inhibit ors in pimasertib‐resistant human lung and colorectal cancer cells
    541. The Role of mTOR inhibit ors in Liver Transplantation: Reviewing the Evidence
    542. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibit ors of the mammalian target of rapamycin (mTOR ): Optimization of the 1-substituent
    543. [Pi3k -AKT-mTOR pathway inhibit ors].
    544. inhibit ion of Pi3k -Akt-mTOR Signaling in Glioblastoma by mTOR C1/2 inhibit ors
    545. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
    546. Differentiating the mTOR inhibit ors everolimus and sirolimus in the treatment of tuberous sclerosis complex
    547. Treatment outcome with mTOR inhibit ors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
    548. mTOR inhibit ors: Do They Help Preserve Renal Function?
    549. mTOR , p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and Pi3k /mTOR inhibit ors in human bronchial carcinoids
    550. The therapeutic potential of mTOR inhibit ors in breast cancer
    551. Pi3k -AKT-mTOR inhibit ors in breast cancer s: From tumor cell signaling to clinical trials
    552. Maximizing the clinical outcome with mTOR inhibit ors in the renal transplant recipient: defining the role of calcineurin inhibit ors
    553. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7 Ralpha signaling.
    554. Catalytic mTOR inhibit ors can overcome intrinsic and acquired resistance to allosteric mTOR inhibit ors
    555. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.
    556. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
    557. Role of mTOR inhibit ors in epilepsy treatment
    558. “Overcoming breast cancer drug resistance with mTOR inhibit ors”. Could it be a myth or a real possibility in the short-term future?
    559. Safety of mTOR inhibit ors in adult solid organ transplantation
    560. mTOR inhibit ors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma
    561. Synergistic antiproliferative effect of mTOR inhibit ors in combination with 5‐fluorouracil in scirrhous gastric cancer
    562. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR ) inhibit ors
    563. mTOR inhibit ors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibit or lapatinib (Tykerb®)
    564. Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR inhibit ors
    565. mTOR inhibit ors as a new therapeutic option for epilepsy
    566. mTOR inhibit ors in the management of hormone receptor-positive breast cancer : the latest evidence and future directions
    567. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    568. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibit ors: Discovery of highly potent and selective analogs with improved human microsomal stability
    569. FBXW7 Mutations in Patients with Advanced cancer s: Clinical and Molecular Characteristics and Outcomes with mTOR inhibit ors
    570. Use of APO2L/TRAIL with mTOR inhibit ors in the treatment of glioblastoma multiforme
    571. Discovery and Assembly-Line Biosynthesis of the Lymphostin Pyrroloquinoline Alkaloid Family of mTOR inhibit ors in Salinispora Bacteria
    572. Benchmarking effects of mTOR , Pi3k , and dual Pi3k /mTOR inhibit ors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    573. The role of mTOR inhibit ors for treatment of sarcomas
    574. Combining mTOR inhibit ors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination
    575. mTOR inhibit ors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation
    576. inhibit ors of Pi3k /Akt and/or mTOR inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 inhibit or and Interferon,
    577. Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibit ors: current and emerging therapeutic options
    578. Combining mTOR inhibit ors with Chemotherapy and Other Targeted Therapies in Advanced Breast cancer : Rationale, Clinical Experience, and Future Directions
    579. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibit ors
    580. inhibit ion of mTOR Pathway Sensitizes Acute Myeloid Leukemia Cells to Aurora inhibit ors by Suppression of Glycolytic Metabolism
    581. Paronychia and Pyogenic Granuloma Induced by New Anticancer mTOR inhibit ors
    582. mTOR inhibit ors counteract tamoxifen-induced activation of breast cancer stem cells
    583. Resistance to mTOR Kinase inhibit ors in Lymphoma Cells Lacking 4EBP1
    584. The inhibit ion of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibit ors
    585. mTOR inhibit ors in pediatric kidney transplantation
    586. mTOR inhibit ors and dyslipidemia in transplant recipients: A cause for concern?
    587. The Role of mTOR inhibit ors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions
    588. mTOR inhibit ors in advanced breast cancer : Ready for prime time?
    589. Innovations therapy: mammalian target of rapamycin (mTOR ) inhibit ors for the treatment of neuroendocrine tumors
    590. mTOR inhibit ors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation
    591. Therapeutic activity of mTOR inhibit ors in mantle cell lymphoma: Clues but no clear answers
    592. Use of mTOR inhibit ors in chronic heart transplant recipients with renal failure: Calcineurin-inhibit ors conversion or minimization?
    593. Is There a Role for Proliferation Signal/mTOR inhibit ors in the Prevention and Treatment of De Novo Malignancies After Heart Transplantation? Lessons Learned From Renal Transplantation and Oncology
    594. Development of ATP-Competitive mTOR inhibit ors
    595. The role of mTOR inhibit ors in the inhibit ion of growth and cortisol secretion in human adrenocortical carcinoma cells
    596. Fused bicyclic mTOR inhibit ors
    597. mTOR inhibit ors radiosensitize PTEN‐deficient non‐small‐cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
    598. Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibit ors
    599. Dual Pi3k /mTOR inhibit ors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic cancer Cells through Suppression of mTOR C2
    600. Potential of mTOR inhibit ors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
    601. Identification of 2-oxatriazines as highly potent pan-Pi3k /mTOR dual inhibit ors
    602. Recent advances in the development of selective, ATP-competitive inhibit ors of mTOR .
    603. ATP-Competitive inhibit ors of mTOR : An Update
    604. Can mTOR inhibit ors reduce the risk of late kidney allograft failure?
    605. inhibit ion of mTOR pathway by everolimus cooperates with EGFR inhibit ors in human tumours sensitive and resistant to anti-EGFR drugs
    606. Everolimus and mTOR inhibit ors in liver transplantation: Opening the “box”
    607. Skin cancer in solid organ transplant recipients: are mTOR inhibit ors a game changer?
    608. mTOR inhibit ors Control the Growth of EGFR Mutant Lung cancer Even after Acquiring Resistance by HGF
    609. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibit ors
    610. The pros and the cons of mTOR inhibit ors in kidney transplantation
    611. Ras/Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR Cascade inhibit ors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
    612. The mTOR kinase inhibit ors polarize glioma-activated microglia to express a M1 phenotype
    613. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibit ors
    614. Ophthalmic compositions comprising calcineurin inhibit ors or mTOR inhibit ors
    615. Management of side effects of mTOR inhibit ors in tuberous sclerosis patients
    616. Clinical efficacy of mTOR inhibit ors in solid tumors: a systematic review
    617. inhibit ors of mTOR overcome drug resistance from topoisomerase II inhibit ors in solid tumors
    618. mTOR inhibit ors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours
    619. Mammalian target of rapamycin inhibit ors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin -like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
    620. mTOR inhibit ors in hematologic malignancies.
    621. Thymoma Patients Treated in a Phase I Clinic at MD Anderson cancer Center: Responses to mTOR inhibit ors and Molecular Analyses
    622. inhibit ion of autophagy sensitizes malignant pleural mesothelioma cells to dual Pi3k /mTOR inhibit ors
    623. mTOR inhibit ors in Castration-Resistant Prostate cancer : A Systematic Review
    624. Gerosuppression by pan-mTOR inhibit ors
    625. A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death
    626. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress : potential role in obesity
    627. Pi3k /Akt and mTOR /p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress -induced apoptosis
    628. Bridges between mitochondrial oxidative stress , ER stress and mTOR signaling in pancreatic β cells
    629. Mammalian Target of Rapamycin (mTOR ) inhibit ion with Rapamycin Improves Cardiac Function in Type 2 Diabetic Mice
      POTENTIAL ROLE OF ATTENUATED oxidative stress AND ALTERED CONTRACTILE PROTEIN EXPRESSION
    630. Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress -mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
    631. inhibit ion of Pi3k /AKT/mTOR axis disrupts oxidative stress -mediated survival of melanoma cells
    632. Melatonin represses oxidative stress ‐induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibit ion of Ras
    633. Tuberous Sclerosis Complex Activity Is Required to Control Neuronal Stress Responses in an mTOR -Dependent Manner